Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Bevacizumab rechallenge after first line maintenance bevacizumab.

Bevacizumab rechallenge after first line maintenance bevacizumab. Gynecol Oncol. 2012 May; 125(2):510-1.

View in: PubMed

© 2021 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.